Manufacturing AsymBio to secure $184m to support growth in biologics manufacturing Pharmaceutical Business ReviewThe funds will be used for AsymBio's principal business operations and drive further expansion of its manufacturing capacity.Read full story pharminent August 5, 2026 (Last updated: August 5, 2026) Pharmaceutical Business Review The funds will be used for AsymBio’s principal business operations and drive further expansion of its manufacturing capacity. Read full story Post navigation Previous: Pfizer Axes Ex-Metsera Obesity Asset and GIPR Prospect in Quarterly Pipeline ClearoutNext: Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 Related Stories Manufacturing BMS banks on Texas for $2.3bn multi-modal manufacturing facility pharminent August 11, 2026 Manufacturing Lilly and Resilience invest $750M in diabetes and obesity drug device supply pharminent July 31, 2026 Manufacturing GSK Cambridge Move Signals Shift in Drug Scale-Up Strategy pharminent July 29, 2026
